Allan Camaisa, Calidi Biotherapeutics CEO (via website)
June 23, 2023 10:36 AM EDTUpdated 02:19 PM
Financing

On­colyt­ic virus start­up Ca­li­di se­cures $25M to­ward Se­ries B round

Paul Schloesser

Associate Editor

Ca­li­di Bio­ther­a­peu­tics, a San Diego biotech work­ing on de­vel­op­ing al­lo­gene­ic cell de­liv­ery of on­colyt­ic virus­es, said Fri­day that in­vestors have com­mit­ted $25 mil­lion to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times